PhoreMost expands into new facility at Unity Campus, Cambridge, UK

New state-of-the-art facility has been designed to support PhoreMost’s phenotypic screening expertise

19 Jan 2022
Rory Shadbolt
Publishing / Media

Industry news

PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets has announced it has relocated its headquarters to Unity Campus, a high-specification technology and innovation park, owned by leading regional property developers and investors, Howard Group, in south Cambridge.

Designed to support PhoreMost’s phenotypic screening requirements and expertise, the new bespoke 14,900 sq ft state-of-the-art facility is split equally between office and laboratory space, with an additional 4,000 sq ft of warehouse storage. The space, within The Works, Unity Campus’ latest combined office and R&D building, enables the Company to add in-house flow cytometry and imaging capabilities. Nearly doubling the size of its previous facilities, the relocation accommodates PhoreMost’s accelerated expansion and ongoing recruitment efforts within one location, including the recent appointment of Dr. Christian Dillon as Chief Scientific Officer.

Based within the South Cambridge Science Cluster, PhoreMost’s relocation to Unity Campus places the Company in close proximity to numerous innovative life science and technology organizations, opening up opportunities for further collaborations with potential partners and researchers based at the Campus.

Dr. Chris Torrance, CEO, PhoreMost, said: “Our move to Unity Campus follows a significant year for the Company, including a successful £33M Series B investment round in March 2021. As a team, remaining within the Cambridge biotech cluster is important, to help fuel new strategic collaborations, and support those already in progress. This move brings the whole team together in one site, where previously we were split across two buildings. With further space available at Unity Campus, we are well-positioned to continue to advance and expand our drug discovery programs across high value, but under-served, therapeutic areas.”

Katherine Friend, Director - Investment & Asset Management, Howard Group, added: “The relocation of PhoreMost’s headquarters to Unity Campus exemplifies the specialist network of innovative, agile, science and technology organizations we are establishing here. We have thoroughly enjoyed working with the Phoremost team to tailor their new laboratory and office space within The Works and are excited to welcome them at such a pivotal time in the Company’s development. We look forward to continuing to work collaboratively with PhoreMost as it continues to grow.”

Having completed The Works in 2020, the second phase of Howard Group’s re-development of Unity Campus is now being brought forward. In response to market demand for agile, flexible science space, Phase 2 will consist of three buildings - totaling 95,000 sq ft - all specifically designed to provide high-quality accommodation for life science occupiers. Each building will consist of ground, first and second-floor office, and laboratory accommodation, with landlord plant provision above. Subject to planning, it is anticipated that Phase 2 will be available from Q1 2023, with units from 10,000 sq ft now available for pre-let. Howard Group welcomes inquiries from potential occupiers wishing to engage at this early stage to enable bespoke requirements to be taken into account.

In addition to Foremost, current life sciences occupiers at Unity Campus include Aqdot, IONTAS, Liminal Bioscience, and Sareum.

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>

Links

Tags

Flow Cytometry / Cell CountingFlow cytometers are used to count, sort and examine multiple characteristics of cells. Other cell analysis equipment includes image cytometers, cell counters, fluorescence-activated cell sorters (FACS), magnetic-activated cell sorters (MACS), and a range of flow cytometry assay kits. Flow cytometers can reveal information on cell viability, cell proliferation, apoptosis and cell cycle progression, as well as identify cell populations and intracellular or cell-surface molecules. Additionally, some flow cytometers, known as FACS, have an additional sorting function after analysis. Cell counters and image cytometers count live and dead cell populations and can also conduct cell proliferation assays. Find the best flow cytometers, cell counters and cell sorters in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.Drug DiscoveryDrug discovery is the process of identifying potential new medications, involving stages such as target identification, compound screening, and preclinical development. It relies on cutting-edge technologies like high-throughput screening, artificial intelligence, and molecular modeling to accelerate the identification of drug candidates. Drug discovery plays a pivotal role in developing new therapies for diseases ranging from cancer to rare genetic disorders. Browse our peer-reviewed product directory to find the latest drug discovery technologies, compare options, check customer feedback, and get pricing directly from manufacturers.Drug DevelopmentDrug development refers to the process of bringing a new drug to market.Drug Discovery & Development Screening
PhoreMost expands into new facility at Unity Campus, Cambridge, UK